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Abstract
MicroRNAs (miRNAs) are small RNAs of 18–25 nucleotides (nt) in length that play important roles
in regulating a variety of biological processes. Recent studies suggest that cellular miRNAs may
serve to control the replication of viruses in cells. If such is the case, viruses might be expected to
evolve the ability to modulate the expression of cellular miRNAs. To ask if expression of HIV-1
genes changes the miRNA profiles in human cells, we employed a high throughput microarray
method, termed the RNA-primed Array-based Klenow Enzyme (RAKE) assay. Here, we describe
the optimization of this assay to quantify the expression of miRNAs in HIV-1 transfected human
cells. We report distinct differences in miRNA profiles in mock-transfected HeLa cells versus HeLa
cells transfected with an infectious HIV-1 molecular clone, pNL4-3.
Findings
MicroRNAs (miRNAs) are small RNAs of 18–25 nucle-
otides (nt) in length that are involved in the regulation of
a variety of biological processes including developmental
timing, signal transduction, apoptosis, cell proliferation
and tumorigenesis [1-3]. Recent studies indicate that cel-
lular miRNAs can variably inhibit [4] or promote [5] viral
replication. Viruses, on the other hand, seem to have
developed strategies which include virus-encoded RNAi
suppressors [6-12] and/or virus-encoded miRNAs [13-
19]. Mechanistically, a current view is that miRNAs func-
tion to silence gene expression through imperfect base-
pairing with cognate transcripts. Since RNA silencing
mediated by miRNA does not require perfect sequence
complementarity, one miRNA can target multiply differ-
ent mRNAs [20]. It is conceivable that viruses may seek to
alter cellular miRNA expression in ways that benefit viral
replication. Extant findings support such a notion since
several viruses have been found to encode RNAi suppres-
sors which could function to influence the cell's overall
miRNA milieu [6-12].
For HIV-1, it has been proposed, based on in vitro assays,
that Tat can partially repress the processing activity of
Dicer [21]. Because Dicer is involved in the maturation of
cellular miRNAs, we wondered how miRNA profiles in
human cells that express HIV-1 proteins might differ from
counterpart cells that do not express viral genes. To ask if
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HIV-1 alters the expression of host miRNAs, we employed
a high throughput microarray approach to quantify
changes in miRNA expression. We used a platform based
on the RNA-primed Array-based Klenow Enzyme (RAKE)
assay. RAKE originally described by Nelson and col-
leagues is a microarray assay which uses on-slide enzy-
matic reactions and primer extension [22]. We printed
specific DNA oligonucleotide probes which contain three
distinct elements onto a microarray glass slide (Fig 1A).
The three different elements include a 5' linker containing
a constant nucleotide sequence with amine-modified
5'end for effective slide conjugation; a 3' anti-miRNA ele-
ment of variable sequence which is complementary to
specific miRNA; and a poly-thymidine region which
allows for primer extension and labeling of hybridized
miRNAs (Fig 1B). It is important to note that RAKE does
not employ a sample amplification step; and the enzymes
(Klenow and exonuclease I) used in this assay work in an
unbiased, substrate sequence-independent way [23].
Thus, RAKE-signals faithfully reflect the true amount of
miRNAs in the samples being tested. This contrasts with
some conventional microarray methods which use RNA
ligase to add linkers on both ends of transcripts for subse-
quent sample amplification. The enzyme kinetics of RNA
ligase varies depending on substrate sequences; thus,
amplified samples may inaccurately represent that in the
original starting population [24,25]. Moreover, complete
sequence complementarity of the 3'end of miRNA with
the DNA oligonucleotide probe used in RAKE is abso-
lutely required for the primer extension step. Since many
mature miRNAs differ from their precursor forms and
their paralogs in the 3'end sequence, this property offers a
specificity advantage to RAKE over several other microar-
ray methodologies.
To validate and optimize our RAKE analysis, we first
printed, based on the published miRNA literature, a small
number of DNA probes on glass slides. Our initial sam-
pling set was designed to distinguish between miRNAs
reported to be expression-specific for Jurkat versus HeLa
Schematic diagram of the RAKE assay Figure 1
Schematic diagram of the RAKE assay. A) The DNA oligonucleotide probe for miRNA detection is composed of three 
elements. The 5' linker region contains a constant nucleotide sequence (5'GTCGTGACTGGGAATAGCCTG3') with an 
amine-modified 5'end which permits the probe to conjugate efficiently to the epoxy-coated microarray glass slide. The anti-
miRNA region contains a sequence complementary to specific miRNA (for instance, anti-hsa-let-7a 
5'AACTATACAACCTACTACCTCA3') for capturing the cognate miRNA (hsa-let-7a 
5'UGAGGUAGUAGGUUGUAUAGUU3'). The poly-thymidine region acts as a template for primer extension of the hybrid-
ized miRNA using biotinylated-dATP. B) Small RNAs isolated from cells are hybridized to the microarray slide described in A. 
After washing, unhybridized single-stranded DNA probes (ssDNA probes) are removed by exonuclease I. Digested nucleotides 
are then removed leaving the hybridized miRNAs for primer extension. The poly-thymidine region now acts as a template for 
the hybridized miRNA to be extended using Klenow (3'→5' exo-) in the presence of biotinylated-dATP. Streptavidin-Alexa 
fluor 555 is then used to bind the biotin group permitting the fluorescent detection of hybridized miRNAs using a GenePix 
4000B microarray scanner (Axon/Molecular Dynamics).Retrovirology 2005, 2:81 http://www.retrovirology.com/content/2/1/81
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Verification of the specificity and sensitivity of RAKE Figure 2
Verification of the specificity and sensitivity of RAKE. A) (a) A prototype small microarray designed to detect a limited 
number of miRNAs was first used to monitor the specificity of miRNA expression in HeLa and Jurkat cells. For purposes of 
verifying internal reproducibility of hybridization, each probe on the microarray slide was printed 4 times (spots 1, 2, 3 and 4 
labeled at top of each column). The identity of individual probe is labeled next to the slide. Red left-hand filled circle indicates 
the miRNA expected to be expressed in HeLa cells. Red right-hand filled circle indicates the miRNA expected to be expressed 
in Jurkat cells. Red fully-filled circle indicates the miRNA expected to be present in both HeLa and Jurkat cells. Unfilled circle 
indicates the miRNA not expected to appear in either HeLa or Jurkat cells. Orange fully-filled circle represents "spike-in" oligos 
included act as positive controls to monitor successful hybridization performance. (b) We hybridized small RNAs isolated from 
HeLa (Left panel) and Jurkat cells (right panel) using microarray slides described in (a). Signals appear as green dots (fluores-
cence at 532 nm). With the exception of hsa-miR-142-3p in Jurkat cells, cell-specific signals were observed in the microarray 
hybridizations in patterns consistent with that expected for HeLa and Jurkat cells. 10-5 M of "spike-in" oligo (ath-miR-157a) was 
included in the experiment as an indicator of the maximum saturating signal from RAKE (saturated signals appear in white 
dots). Data are presented here in raw form without further modification or normalization. B) We demonstrated the specificity 
of RAKE by hybridizing small RNA isolated from Jurkat cells to a subset of polymorphic miRNA (hsa-let-7 family). The names, 
sequences of the miRNAs and the raw signals detected from the RAKE assay are listed. hsa-let-7c and hsa-let-7f differ from 
hsa-let-7a in one nucleotide base (highlighted in yellow). However, the signals detected for hsa-let-7a are approximately 16 
times less than that detected for hsa-let-7c and hsa-let-7f, suggesting that RAKE can distinguish a single base difference. Simi-
larly, the signals detected for hsa-let-7c are approximately 2.5 times higher than that detected in hsa-let-7b which has only one 
nucleotide difference (highlighted in yellow). C) To estimate the sensitivity of the RAKE assay, different concentrations of 
"spike-in" oligo (ath-miR-157a) were hybridized to the small microarray described in (a). The raw data from the four different 
hybridization reactions (each measuring four replicated spots) are presented on the X-axis at the indicated concentrations of 
"spike-in" target oligo. Signal intensity of each spot (median pixel) was measured and converted into log2 scale. A linear range of 
detection can be observed when the log2 values are plotted against the concentration of the "spike-in" oligos between 10-8 to 
10-6 M. An approximate minimum detectable concentration in this RAKE assay is 10-7 M. Error bars represent the standard 
deviation of the values from the four replicated spottings of each probe.Retrovirology 2005, 2:81 http://www.retrovirology.com/content/2/1/81
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cells [22] (Fig 2Aa). We wanted to verify that if we hybrid-
ized our slides with miRNAs isolated from HeLa cells,
then only HeLa-specific signals would appear in our RAKE
assay. Similarly, we wanted to validate the converse for
Jurkat miRNAs. When we performed the assays, we indeed
replicated the expected cell-specific miRNA expression
patterns, with a single exception for hsa-miR-142-3p. Hsa-
miR-142-3p was reported by others to be expressed in Jur-
kat cells, but was not detected by us in those cells (Fig
2Ab). It is unclear why hsa-mirR-142-3p was not detected
in our assay, but a trivial explanation might be because
there are many different lines of Jurkat cells used in vari-
ous laboratories. We note that our routinely included
"spike-in" oligo (ath-miR-157a), used as a control for the
success of the enzymatic reaction, behaved reproducibly
from experiment to experiment. We also chose a subset of
polymorphic miRNA (hsa-let-7 family) in order to verify
the specificity of hybridization detected by our RAKE.
Using small RNAs isolated from Jurkat cells for hybridiza-
tion, RAKE was able to distinguish a single nucleotide dif-
ference (hsa-let-7a from hsa-let-7c and hsa-let-7f; hsa-let-
7c from hsa-let-7b), suggesting the conditions used by us
are highly stringent (Fig 2B).
The sensitivity of RAKE was evaluated by hybridizing
microarray slides with varying amounts of ath-miR-157a.
As shown in Fig 2C, RAKE provided robust signals when
challenged with as low as 10-7 M of substrate, and offered
linear readouts in log2 scale for substrates in the 10-8 to 10-
6 M range. We defined our signal as the median of fore-
Changes in miRNA profile after transfection of HeLa cells with HIV-1 pNL4-3 Figure 3
Changes in miRNA profile after transfection of HeLa cells with HIV-1 pNL4-3. A) Example slide readouts are shown 
using small RNAs isolated from mock-(left panel) and pNL4-3-transfected HeLa cells (right panel). Here, each probe was 
printed 5 times in a row (spots 1, 2, 3, 4 and 5 labeled at top of the arrays). Signals appear as green dots. B) Cell plot analysis of 
the miRNA expression profiles of mock-transfected HeLa cells (samples 1 and 2) and pNL4-3-transfected HeLa cells (sample 
3). Each colored block represents the expression of one miRNA (labeled on the left) in the indicated sample. Signals acquired 
from the microarray are converted into color (high signal = red; low signal = black; no signal = green). Samples 1 and 2 (mock-
transfected HeLa cells) show highly similar color patterns while sample 3 (pNL4-3-transfected HeLa cells) shows reduced 
miRNA expression (i.e. only a few blocks appear red in color). The red-boxed miRNAs were chosen for real-time PCR valida-
tion in figure 5.Retrovirology 2005, 2:81 http://www.retrovirology.com/content/2/1/81
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Scatterplot analysis of the changes in miRNA expression after transfection of HeLa cells with HIV-1 clone pNL4-3 Figure 4
Scatterplot analysis of the changes in miRNA expression after transfection of HeLa cells with HIV-1 clone 
pNL4-3. Pairwise comparison of two mock-transfected HeLa cells (sample 1 vs. sample 2) to each other and to pNL4-3-trans-
fected HeLa cells (sample 3) by scatterplot analysis. Spots associated with individual miRNAs were collected and converted 
into log2 scale. Each datum point represents one unique probe sequence (based on median values from 4 replicated spots from 
each hybridization). miRNAs with similar signal intensities from the two samples being compared line up together on a 45° 
diagonal line (center line). This is most clearly seen in (A), where two mock-transfected HeLa cells samples are compared to 
each other. In this comparison, most of the dots line up together at the center line supporting that the miRNA expression pat-
terns of the two samples (1 and 2) are highly similar. By contrast, miRNAs with expression levels higher or lower in one sam-
ple than the other sample are expected to produce dots that deviate from the center line. The dots are allocated to positions 
that are above or below than the +2 fold or -2 fold line when the differences are greater than two folds. This was the case 
when the log2 values of sample 3 (pNL4-3-transfected HeLa cells) was plotted against sample 1 (B) or 2 (C). The miRNAs with 
reduced expression in sample 3 are allocated to positions below the -2 fold line. The red-circled miRNAs were chosen for 
real-time PCR validation as shown in figure 5.Retrovirology 2005, 2:81 http://www.retrovirology.com/content/2/1/81
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Validation of RAKE using real-time PCR Figure 5
Validation of RAKE using real-time PCR. Fluorescence signals from each of the 45 PCR cycles were collected and con-
verted into log10 values. The log10 fluorescence values (Y-axis) of each sample are then plotted against the PCR cycles (X-axis) 
to generate a sigmoid curve. CT (threshold-cycle; dotted line) determines the minimum PCR cycle required for the reaction to 
give a threshold fluorescence signal. Samples with more templates require fewer PCR cycles to reach the threshold. Compari-
son of the miRNA expression levels in pNL4-3- (green curve) and mock-transfected HeLa cells (red curve) are facilitated by 
using cellular small nuclear U6 RNA (blue curve from mock, and orange curve from pNL4-3; please note that the blue and 
orange control curves superimpose closely on top of each other, supporting the validity of the PCR conditions for comparing 
the experimental curves) and an empirically established unchanged miRNA (mi-526c; mock and pNL4-3 samples are shown in 
red and in green curves, respectively) as normalization references (A). Selected pNL4-3-downregulated miRNAs [miR-93 (B), 
miR-148b (C), miR-221 (D) and miR-16 (E)] were validated by real-time PCR. Real-time PCR curves for U6 RNA control 
(mock and pNL4-3) are included in all of the graphs for normalization. Signals of the selected miRNAs measured in the RAKE 
assay from different samples (1, 2 and 3) are presented in table form at the top of each graph.
MI2
B P.,
	
MI2
B MOCK	
PL51$ 6DPSOHPRFN 6DPSOHPRFN 6DPSOHS1/
KVDPL5E   

MI2
 MOCK	
MI2
 P.,
	
PL51$ 6DPSOHPRFN  6DPSOHPRFN 6DPSOHS1/
KVDPL5   

MI2
 P.,
	
MI2
 MOCK	
PL51$ 6DPSOHPRFN 6DPSOHPRFN 6DPSOHS1/
KVDPL5   

5 MOCK	
5 P.,
	
4
'RZQUHJXODWHGPL51$V
#4 #
#4 #4
8QFKDQJHGPL51$V
#4
4ESTED MI2.! P.,
	
4ESTED MI2.! MOCK	
MI2
 P.,
	
MI2
 MOCK	
PL51$ 6DPSOHPRFN 6DPSOHPRFN 6DPSOHS1/
KVDPL5   

MI2
C MOCK	
MI2
C P.,
	
PL51$ 6DPSOHPRFN 6DPSOHPRFN 6DPSOHS1/
KVDPL5F   

!	
"	 #	
$	 %	Retrovirology 2005, 2:81 http://www.retrovirology.com/content/2/1/81
Page 7 of 8
(page number not for citation purposes)
ground spot fluorescence at 532 nm wavelength minus
background (defined by surrounding pixel intensity);
negative values were reset as zero.
After optimization of conditions in initial small scale
tests, we next printed microarray slides which contained
312 individual probes based on published sequences of
all-known mature human miRNAs at time of slide pro-
duction. We separately hybridized individual slides with
small RNAs (20 µg per slide) isolated from mock-trans-
fected HeLa or HeLa cells transfected with infectious HIV-
1 molecular clone, pNL4-3 (see Fig 3A for actual examples
of typical results). The results from cell plot analysis of
repeated hybridizations indicated that large numbers of
miRNAs in pNL4-3-transfected HeLa cells, when com-
pared to mock-transfected HeLa cells, were significantly
downregulated (Fig 3B). Clear differences were revealed in
comparisons of mock-transfected HeLa cells to pNL4-3-
transfected HeLa cells using scatterplot analysis (Fig 4).
Although many miRNAs were reduced in expression in
the HeLa-pNL4-3 sample (e.g. ~43% of all of the miRNAs
were more than two-fold downregulated), the majority of
miRNAs remained unchanged, suggesting that the
observed results are not due to non-specific generalized
cellular toxicity. Interestingly, in our assays, miRNAs
upregulated by transfected pNL4-3 were exceedingly rare.
Pending further understanding of mechanisms, it is con-
ceivable that the downregulation of mature miRNAs as
detected by our RAKE assay may be due to the Dicer-sup-
pressive effect exerted by HIV-1 Tat protein and/or TAR
RNA [21,26].
To confirm our RAKE assays, we tested selected results
using real time PCR as described by Shi and Chiang [27].
Using these assays, we checked the RAKE results in HeLa
cells for four HIV-1 downregulated miRNAs (miR-93,
miR-148b, miR-221 and miR-16) (Fig 5B, C, D and 5E).
We used two normalization controls, a miRNA (miR-
526c) whose expression was found empirically to be
reproducibly unchanged in our assays, and a miRNA-
unrelated small cellular RNA, the small nuclear U6 RNA
(Fig 5A). Real time PCR results confirmed the findings
from RAKE.
In conclusion, we describe here a rapid assay that moni-
tors reproducible changes in cells transfected with HIV-1
infectious molecular clone, pNL4-3. We find that a domi-
nant pattern of response in HeLa cells to pNL4-3 transfec-
tion is the downregulated expression of many miRNAs.
Studies are ongoing to examine changes in miRNA expres-
sion patterns in human cells (primary and T cell lines)
after infection with HIV-1.
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